ACE-031 1mg

Quickstart Highlights

Reference-linked protocol details for ACE-031 1mg.

Reference title: ACE-031 Dosing Protocols and Administration | Peptide Protocol Wiki
Product: ACE-031 1mg vial
A high-caution myostatin-pathway research entry for ActRIIB signaling and safety review.
Source page: Open source

Protocol Overview

ACE-031 is a soluble activin receptor type IIB fusion-protein research product developed to modulate myostatin/activin signaling. Clinical development raised safety concerns such as bleeding-related and vascular findings, so this should be handled as high-caution research context only with cardiovascular, bleeding, cancer, and endocrine history reviewed by a clinician.

Myostatin/activin pathway context
High-caution safety review
Bleeding and vascular-risk screening
Clinician-guided discussion

Recommended Source

This protocol is linked to the workbook reference source below.

ACE-031 Dosing Protocols and Administration | Peptide Protocol Wiki Open source

Dosing & Reconstitution Guide

Muscle growth and myostatin inhibition (discontinued investigational compound)

Amount
1-3 mg/kg
Frequency
Every 2 weeks
Duration
12 weeks (based on Phase 2 DMD protocol; trial was terminated early)
Route
Schedule
Timing
No specific time of day required; allow solution to reach room temperature before injection
✓ Rotate injection sites
Repeatable
Yes
Storage: ACE-031 protein solutions should be stored at 2-8 degrees Celsius (refrigerated). Protect from freezing and agitation. Protein solutions are sensitive to repeated freeze-thaw cycles which can cause aggregation and loss of activity.
CBC with differential
When: Baseline
Why: Baseline blood cell counts
CMP (Comprehensive Metabolic Panel)
Why: Liver and kidney function baseline
DEXA scan
Why: Baseline lean body mass and fat mass measurement
Bone-specific alkaline phosphatase
Why: Baseline bone formation marker
Coagulation panel (PT/INR, aPTT)
Why: Baseline vascular/bleeding risk given epistaxis concern
When: 12 weeks
Why: Assess lean mass and fat mass changes
→Contraindication: Avoid in patients with bleeding disorders, vascular malformations, or hereditary hemorrhagic telangiectasia; discontinued due to vascular safety signals

Dosing Protocol

Free access to research-backed dosing information for all peptides.

Phase 1 Study -- Single Ascending Doses#

Dose Cohort	Dose (mg/kg)	Route	Observations
1	0.02	SC	Well tolerated; minimal pharmacodynamic effect
2

150+ peptide profiles · 30+ comparisons · 18 research tools
Free access to complete dosing tables and protocol details.
ACE-031 was supplied as a sterile solution for subcutaneous injection in clinical trials. As a discontinued investigational compound, no commercial formulation exists. Research-grade material requires verification of protein integrity, sterility, and endotoxin content before use.
✓Subcutaneous (abdomen)
✓Subcutaneous (thigh)
ACE-031 protein solutions should be stored at 2-8 degrees Celsius (refrigerated). Protect from freezing and agitation. Protein solutions are sensitive to repeated freeze-thaw cycles which can cause aggregation and loss of activity.
Compare these clinical doses with what 15+ community members report using.
Based on 15+ community reports
Review safety warnings and contraindications before starting any protocol.
The Phase 1 study evaluated single subcutaneous doses of ACE-031 in healthy postmenopausal women using a dose-escalation design.

Important Note

This page is informational and does not authorize use. Peptify clients should complete assessment, disclose medications and health history, and follow the clinician-approved plan only.

Do not start, stop, combine, or change a protocol based only on website content.
Emergency symptoms require urgent medical care, not a website or routine follow-up message.

References

Reference source used for this protocol page.

ACE-031 Dosing Protocols and Administration | Peptide Protocol Wiki Open source
Peptify Reconstitution Guide

Contents